pSivida (NSDQ:PSDV) started recruiting patients in a Phase III U.S. trial for its eyelash-sized drug/device combination, an implant designed to treat ocular swelling that can lead to blindness.
pSivida Corp.
pSivida gains big on buyout rumor
Shares of ophthalmology company pSivida (NSDQ:PSDV) hit a 52-week high today on speculation from a Seeking Alpha blogger that it’s ripe for an acquisition this year.
PSDV shares hit $3.96 each today, a 52-week high, having gained some 15.5% since a blogger writing as "Bob’s Stocks" published the rumor yesterday.
pSivida wins approval for Iluvien in Germany
pSivida’s new Iluvien approval attempt focuses on safety
pSivida takes another stab at FDA approval for Iluvien
U.K. regulators deal pSivida, Alimera a blow
NinePoint lands CE Mark for endomicroscopic imaging system | Regulatory Roundup
AngioDynamics resumes NanoKnife shipments following FDA warning | Regulatory Roundup
Report: Covidien to acquire superDimension for $350M | Wall Street Beat
Covidien (NYSE:COV) is set to close a $350 million buyout of Israeli lung diagnosis firm superDimension by the end of the week, according to Israeli business journal Calcalist.
Founded in Tel Aviv by Pinchas Gilboa, Minneapolis-based superDimension, which employs about 120 people worldwide, also has offices in Dusseldorf, Germany.
Zimmer axes jobs to cut costs ahead of med-tech tax | Personnel Moves
Zimmer Holdings (NYSE:ZMH) announced layoffs at its Warsaw, Ind., headquarters, pointing to the expected burden of the medical device tax as partly responsible for some of the losses.
The orthopedics device maker plans to offset the entire burden posed by the impending 2.3% device levy in 2013 through cost-cutting efforts, part of which include layoffs.
Thoratec soars after killing it in Q3 | Earnings Roundup
Thoratec (NSDQ:THOR) shares are up more than 11% today after the heart pump maker put mid-double-digit profit growth numbers on the board for the 4th quarter and full-year 2011.
The Pleasanton, Calif.-based cardiac assist device maker logged profits of $15.3 million, or 25 cents per diluted share, on sales of $109.4 million for the 3 months ended Dec. 31, 2011. That’s a 46.4% bottom-line gain and a top-line boost of 12.1%, compared with profits of $10.5 million, or 17 cents diluted EPS, on sales of $97.6 million during Q4 2010.